PharmGKB was pleased to see our pathways featured on two successive covers of the journal Pharmacogenetics and Genomics. Our macrolide antibiotic pharmacokinetics and pharmacodynamics pathway was featured on the cover of the April issue, and our voriconazole pharmacokinetics pathway was featured on the cover of the May issue. PharmGKB curators Dr. Alison Fohner and Julia Barbarino were the respective lead authors on these pathways.
Voriconazole is an antifungal agent used primarily in immunocompromised patients, such as those undergoing organ transplantation. CYP2C19 is the primary enzyme responsible for voriconazole metabolism, and the metabolism and clearance of voriconazole are influenced by CYP2C19 genotype. The voriconazole pathway can be viewed on the PharmGKB website. The Clinical Pharmacogenetics Implementation Consortium (CPIC) also recently released guidelines for voriconazole dosing based on CYP2C19 genotype.
Macrolides are a class of broad spectrum antibiotics of large molecular size, including erythromycin, clarithromycin and azithromycin. Macrolide antibiotics exhibit a number of pharmacogenetic associations with the genes encoding drug transporters and metabolizing enzymes. More information can be found on the macrolide pathway on the PharmGKB website.